Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older

다국어 초록 (Multilingual Abstract)

Background: Older adults are given high priority for coronavirus disease 2019 (COVID-19) vaccination; however, little is known about the safety of vaccines. This study was conducted to examine the safety of the COVID-19 vaccine for people who were ≥ 75 years of age, specifically those who first took two doses of the vaccine at the COVID-19 central vaccination center in South Korea.
Methods: Safety monitoring after the BNT162b2 vaccine was conducted in three ways for older adults who received the first dose of the vaccine at our center between April 5 and April 23, 2021. For immediate adverse reactions, every person who was vaccinated was observed for 15–30 minutes after injection at the center. For active surveillance, a telephone interview was conducted for stratified randomly sampled people after 7 days of each vaccination to enquire regarding types of adverse reactions they experienced, and its severity and duration. For passive surveillance, reported adverse event data were collected from the COVID-19 vaccine adverse event following immunization (AEFI) surveillance system—run by the Korea Disease Control and Prevention Agency (KDCA). The data were then reviewed.
Results: In total, 2,123 older adults received at least one vaccine dose during the study period. The frequency of acute adverse reactions that developed during the observed 15–30 minutes after injection was 8.5 cases per 1,000 doses. None of the reactions was assessed as acute allergic reactions to the vaccine and no cases required special treatment or drug administration. Overall, 638 people were followed up at least once by telephone interview 7 days post vaccination. The overall response rate was 82.3%. The rates of local reactions were 50.3% after the first dose and 45.2% after the second dose, and the rates of systemic reactions were 15.2% and 26.0%, respectively. During the study period, 23 medically attended adverse events (5.4 cases per 1,000 administered doses) were reported to the KDCA AEFI surveillance system. The most common symptoms of medically attended cases were nonspecific general weakness (26%) and dizziness (26%), followed by muscle pain (22%), headache (13%), fever (13%), and skin rash or urticaria (13%). Among them, there were five serious adverse events reported, which required hospitalization, including one death. However, most of them were not related to the vaccines.
Conclusion: BNT162b2 vaccination was tolerable among adults who were ≥ 75 years of age.

참고문헌 (Reference)

• 1 World Health Organization, "WHO coronavirus (COVID-19) dashboard"
• 2 Food and Drug Administration, "Vaccines and related biological products Advisory Committee Meeting December 10, 2020, FDA briefing document, Pfizer-BioNTech COVID-19 Vaccine"
• 3 Menni C, "Vaccine side-effects and SARSCoV-2 infection after vaccination in users of the COVID symptom study app in the UK : a prospective observational study" 21 (21): 939-949, 2021
• 4 Klein SL, "The Xs and Y of immune responses to viral vaccines" 10 (10): 338-349, 2010
• 5 Oh HK, "Status of adverse reactions after COVID-19 vaccination in the Republic of Korea, February 26, 2021-March 25, 2021"
• 6 Klein SL, "Sex-based differences in immune function and responses to vaccination" 109 (109): 9-15, 2015
• 7 Walsh EE, "Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates" 383 (383): 2439-2450, 2020
• 8 Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine" 383 (383): 2603-2615, 2020
• 9 Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China" 180 (180): 934-943, 2020
• 10 Korea Disease Control and Prevention Agency, "Press release. COVID-19 vaccination to begin this week"
• 11 Du RH, "Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 : a prospective cohort study" 55 (55): 2000524-, 2020
• 12 Gee J, "First month of COVID-19 vaccine safety monitoring-United States, December 14, 2020-January 13, 2021" 70 (70): 283-288, 2021
• 13 Soiza RL, "Efficacy and safety of COVID-19 vaccines in older people" 50 (50): 279-283, 2021
• 14 Song Joon Young, "Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers" 대한의학회 36 (36): 1-4, 2021
• 15 Choi Min Joo, "Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea" 대한의학회 36 (36): 1-13, 2021
• 16 European Medicines Agency, "Comirnaty: EPAR-product information"
• 17 European Medicines Agency, "COVID-19 vaccine safety update for Comirnaty: 18 June 2021"
• 18 Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology, "CBER surveillance program background rates of adverse events of special interest for COVID-19 vaccine safety monitoring protocol"
• 19 Alroy-Preis S, Milo R, "Booster protection against confirmed infections and severe disease - data from Israel"
• 20 Ozonoff A, "Bell's palsy and SARS-CoV-2 vaccines" 21 (21): 450-452, 2021
• 21 Shemer A, "Association of COVID-19 vaccination and facial nerve palsy : a case-control study" 147 (147): 739-743, 2021
• 22 Harris T, "Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15" 35 (35): 2600-2604, 2017
• 23 Decaroli MC, "Aging and sex hormones in males" 8 (8): 545-570, 2017
• 24 Müller L, "Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination" 2021
• 25 Lee Yun Woo, "Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea" 대한의학회 36 (36): 1-6, 2021
• 26 Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea" 대한의학회 36 (36): 1-9, 2021
• 27 Kim Si-Ho, "Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience" 대한의학회 36 (36): 1-8, 2021